Jubilant Ingrevia Limited: Service-Led CDMO Pivot Drives EBITDA Margin Expansion to 14% Near Bharuch Facilities as Specialty Segment Share Hits 75%
Date : 2026-08-05
Reading : 88
HDIN Executive Takeaways
1. Jubilant Ingrevia Limited [NSE: JUBLINGREA / BSE: 543271] reported FY2026 consolidated total revenue of $503.52 million (₹4,388 Crore), up 5% YoY, with EBITDA expanding 9% YoY to $69.65 million (₹607 Crore) and operating margin improving 51 basis points to 14%.
2. A structural shift elevated Specialty Chemicals to 75% of total corporate EBITDA, anchored by double-digit volume expansion in Vitamin B3 and continuous flow commercialization at the Bharuch hub, offsetting a 4% EBITDA margin compression in Chemical Intermediates.
3. Balance sheet deleveraging compressed Net Debt by 11% YoY to $67.82 million (0.97x EBITDA), providing operational buffer for a >$229.50 million multi-year capital outlay targeting the "Pinnacle 345" vision to triple revenue by FY2029.
Figure Jubilant Ingrevia Limited FY2026 Financial & Operational Master Blueprint
Segmental Realities, Financial Architecture, and Working Capital Diagnostics
Jubilant Ingrevia Limited demonstrated volume-driven top-line growth in FY2026, absorbing deflationary chemical pricing shocks across international markets. Note: All figures are converted at 1 USD = 87.1468 INR. Consolidated Total Revenue reached $503.52 million (₹4,388 Crore / ₹43,880.65 million), up 5% YoY. Profitability metrics scaled across all tiers: Consolidated EBITDA stood at $69.65 million (₹607 Crore), reflecting a 9% YoY growth; Consolidated EBIT reached $49.56 million (₹4,319.04 million); Profit After Tax (PAT) expanded 11% YoY to $31.90 million (₹278 Crore / ₹2,778.99 million). The EBITDA margin expanded by 51 bps to 14%, while net margin remained steady at 6%.
Table Segment Analysis
The company's balance sheet maintains low leverage metrics:
* Net Debt compressed 11% YoY from FY2025 to $67.82 million (₹591 Crore).
* Net Debt-to-EBITDA improved to 0.97x (down from 1.18x in FY2025).
* Consolidated Gearing (Net Debt to Equity) contracted to 0.19x (vs. 0.22x in FY2025).
* Debt Service Coverage Ratio (DSCR) stood at 4.39x.
* Operating Cash Flow (OCF) reached $60.16 million (₹5,242.70 million), achieving high conversion from $69.65 million EBITDA.
* Cash CAPEX Outflows totaled $41.34 million (₹3,602.35 million), delivering Free Cash Flow (FCF) of $18.82 million.
* Consolidated ROCE was recorded at 12.36%, ROE at 9.18%, and Net Capital Turnover Ratio at 14.71x (vs. 16.19x in FY2025 due to ongoing asset commissioning).
Operational working capital compressed to 16% of revenue (down from 18% in FY2025), with net working capital cycle reduced to 59 days (working capital cycle at 62 days vs. 66 days in FY2025).
* Inventory Management: Raw material inventory compressed 8.6% to $36.93 million (₹3,218.45 million); finished goods inventory contracted 15.6% to $33.95 million (₹2,958.69 million). Total inventory write-downs were $0.12 million (₹10.29 million) against a total inventory base of $100.97 million (₹8,799.65 million).
* Receivables & Credit Risk: Undisputed trade receivables <6 months stood at $89.72 million (₹7,818.97 million); 6–12 months receivables totaled $0.09 million (₹7.64 million). Expected Credit Loss (ECL) allowance rose slightly to $0.41 million (₹36.06 million vs. $0.39 million in FY2025), with default provisioning scaled from 0.03% (<6 months) to 32.28% (6–12 months) and 98.67% (>1 year).
* Payables & Supplier Finance: Trade payables stood at $107.94 million (₹9,406.47 million), with Accounts Payable days at 97 days. Supplier financing arrangements covered $52.30 million (₹4,557.81 million) of payables across 90-to-120-day terms.
* Tax & Dividends: Against Profit Before Tax of $42.43 million (₹3,697.40 million), tax expense of $10.54 million (₹918.41 million) yielded an effective tax rate of 24.8% (statutory rate: 25.168%). Non-deductible/exempt items reduced tax liabilities by $1.25 million (₹109.29 million), while foreign sub-rates added $1.10 million (₹95.91 million). The Board declared a final dividend of $0.03 (₹2.50) per share, matching the interim dividend for a total FY2026 payout of $0.06 (₹5.00) per share ($9.14 million / ₹796.41 million total cash allocation), representing a 28.66% payout ratio against PAT of $31.89 million (₹2,778.99 million).
Infrastructure Footprint, R&D Pipeline, and M&A Forensic Audit
Jubilant Ingrevia Limited operates 6 manufacturing hubs (Gajraula, Bharuch, Nira, Savli, Ambernath, Bengaluru) housing over 50 interconnected plants, supported by international distribution hubs in the USA, Belgium, Singapore, and China. Total revenue generated outside India reached 44.32% ($223.16 million / ₹19,447.81 million) across 1,600+ customers in 63 countries. Geographic breakdown: India $284.43 million (₹24,787.18 million / 56.5%); Americas & Europe $161.49 million (₹14,073.52 million / 32.1%); China $19.57 million (₹1,705.36 million / 3.9%); Rest of World $38.03 million (₹3,314.59 million / 7.5%).
Capital expenditure over the last 3 years exceeded $229.50 million (₹2,000+ Crore). Key projects include:
* Bharuch Hub: Commissioned a multipurpose Agro CDMO plant within 14 months (commercial dispatches launched March 2026); operationalized a cGMP Niacinamide facility (WHO-GMP, FSSC 22000 v6, USFDA approved); built a 10MW Captive Power Plant with 98TPH boiler; Multi-Purpose Plant (MPP) under construction.
* Greater Noida Hub: Commenced execution on a clean-room Semiconductor R&D lab for sub-parts-per-billion (ppb) purity chemistries (E-Pyridines, E-Choline Hydroxide).
* Gajraula & Nira Hubs: Installed Variable Frequency Drives on boiler fans, optimized incinerator waste heat recovery, implemented heat recovery systems, and introduced new-age catalysts.
R&D expenditure totaled $4.20 million (₹365.82 million / +4.7% YoY), representing 0.83% of total revenue. Expensed R&D reached $3.69 million (₹321.20 million / 87.8%), while capitalized R&D was $0.51 million (₹44.62 million / 12.2%). R&D operations employ 150 scientists (including 30 PhDs) across 35+ chemistry platforms at 3 centers (Greater Noida, Bharuch, Gajraula). The active pipeline features 50+ products, utilizing continuous flow manufacturing for Niacin/Niacinamide, Agentic AI/GenAI retrosynthesis, and pilot plant testing at Gajraula. Patent disclosures were omitted in filings.
On March 30, 2026, Jubilant Ingrevia Limited acquired 100% of Remidex Pharma Private Limited for a total purchase consideration of $1.868 million (₹162.79 million) [$1.283 million upfront cash; $0.585 million deferred liability]. Acquisition costs of $0.091 million (₹7.93 million) were expensed. Purchase Price Allocation: Net identifiable assets acquired were $1.165 million (₹101.53 million), creating $0.703 million (₹61.26 million) in Goodwill. Assets acquired included PPE of $2.555 million (₹222.63 million), Customer Relationship Intangibles of $0.765 million (₹66.63 million), Other Non-Current Assets of $0.046 million (₹3.99 million), and Current Assets of $0.644 million (₹56.09 million; including $0.181 million inventory, $0.402 million receivables, $0.008 million cash). Identifiable liabilities assumed totaled $2.844 million (₹247.81 million; payables $0.572 million, other financial liabilities $1.148 million). Remidex reported full-year standalone losses of $1.294 million (-₹112.81 million) on revenue of $2.532 million (₹220.62 million), carrying negative net assets of negative $1.162 million (-₹101.30 million). Post-acquisition profit contribution consolidated from March 30–31 was $0.005 million (₹0.45 million).
Table Subsidiary Portfolio Analysis
*Standalone full-year revenue. Post-acquisition consolidated net profit contribution (March 30–31, 2026).
Related Party Transactions (RPT) in FY2026 totaled $82.19 million (₹7,162.72 million) in operating sales and $38.38 million (₹3,344.88 million) in purchases, executed under arm's-length clearance. Sales to JLS NV (Belgium) reached $43.10 million (₹3,755.94 million), making the subsidiary the parent’s single largest customer (9.08% of parent revenue). Sales to JI-USA were $26.78 million; JLS Shanghai $9.38 million; Jubilant Agri & Consumer Products (JACPL) $2.25 million (₹196.19 million). Purchases included $23.81 million (₹2,075.25 million) paid to Jubilant Infrastructure Ltd for SEZ utilities, $7.65 million from JLS Shanghai, $3.90 million from Jubilant Pharmova, $1.59 million from JACPL, and $0.98 million (₹85.40 million) to AMP Energy for solar PPA. Parent intercompany borrowings from JIL stood at $6.83 million (₹595.00 million) at 6.63%–7.07% interest ($3.04 million repaid, $0.639 million interest paid). Parent loans to JASL totaled $4.70 million (₹410.00 million) outstanding ($3.44 million issued in FY2026, generating $0.210 million interest). Cross-charges generated $4.48 million (₹390.21 million), including $1.01 million to Jubilant Biosys and $0.99 million to Jubilant Pharmova. CSR donations to Jubilant Bhartia Foundation totaled $0.728 million standalone ($0.790 million consolidated).
Promoter group shareholding decreased 6.25% in FY2026, from 51.47% to 45.22%. SPB Trustee Co reduced its stake by 2.28% to 18.35%, while Nikita Resources (2.20%) and Jubilant Enpro (1.77%) liquidated their holdings. HSB Trustee Co retained 19.00%. Zero promoter shares are pledged. The 12-member Board includes 6 Independent Directors (50%), featuring 2 women Independent Directors (Sudha Pillai, Ameeta Chatterjee). Executive compensation: Deepak Jain (CEO & MD) received $1.66 million (₹144.58 million / +13.24% YoY / 146.04x median); Hari S. Bhartia (Co-Chairman) received $2.11 million (₹183.78 million / -0.19% YoY / 185.64x median); Vijay Kumar Srivastava (COO) received $0.38 million (₹33.25 million). Average salary increases were 8.80% for non-managerial staff and 8.91% for managerial staff; median salary was $11,360 (₹0.99 million). Key Managerial Personnel turnover was zero, though Ambrish Dixit (President - Specialty Chemicals) resigned effective March 31, 2026. Permanent employee turnover reached 19.6% (female turnover: 25.2%).
ESG Benchmarks: S&P Global CSA score of 74/100 (97th percentile); EcoVadis Silver (92nd percentile); CDP 'B' for Climate and Water. Scope 1 target: -40% by FY2029 (vs. FY2023). Scope 2 emissions fell 24% YoY, reducing net absolute GHG by ~33,944 tCO2e. Renewable power reached 25% (targeting >35% by FY2029 via equity in O2 Renewable Energy XVIII). Specific water consumption dropped 2.8%–3.6%; recycling reached 45%; 3 of 5 plants operate with Zero Liquid Discharge (ZLD). Process safety audit scored in the 83rd percentile. Lost Time Injury Frequency Rate (LTIFR) stood at 0.00x with zero fatalities. Female workforce participation reached 7.2% (targeting 12% by FY2027 under WINGS).
Macro disruptions included Red Sea war risk surcharges of 7%–8%, feedstock shifts via US 45Z ethanol rules, and coal import regulations. USFDA audit of Bharuch site was completed with Zero 483 observations. Net unhedged FX exposure closed at a USD liability of $3.92 million (₹341.63 million) and EUR asset of $0.43 million (₹37.59 million), leaving a 5% USD fluctuation with a $0.14 million (₹12.37 million) impact on PBT, managed via natural hedges.
HDIN Institutional Verdict
Jubilant Ingrevia Limited's FY2026 performance highlights the execution of its portfolio transformation. The Specialty Chemicals vertical now delivers 75% of operating EBITDA, insulating consolidated profitability from commodity pricing cycles. However, three operational vulnerabilities require ongoing evaluation by institutional investors:
1. Sub-Segment Friction: The Chemical Intermediates margin compression to 4% reflects severe Chinese dumping and weakness in the Paracetamol value chain. While backward integration protects volume continuity, asset turnover in base intermediates remains cyclically suppressed.
2. High Subsidiary and Customer Concentration: Crop protection subsidiary Jubilant Agro Sciences Limited (JASL) depends on two global innovators for 86% of its revenue, requiring financial support guarantees from the parent entity despite posting FY2026 net losses of $1.313 million.
3. Integration and Executive Continuity: Managing the integration of Remidex Pharma (acquired with negative net assets of -$1.162 million) alongside the departure of Ambrish Dixit (President - Specialty Chemicals) presents operational integration hurdles as the company executes its $390.15 million peak revenue CDMO pipeline under the "Pinnacle 345" roadmap.
Presentation Download & Video Access:
- Presentation Download: Click the PDF download link under 'Related Topics' to access the full institutional presentation of this report.
- Video Link: Click this link to watch the HDIN analyst briefing on YouTube.
About HDIN Research:
HDIN Research is a global market intelligence and strategic advisory firm specializing in institutional-grade financial analysis, supply chain audits, and macroeconomic forecasting. Our dedicated sector analysts deliver actionable, data-driven insights tailored for private equity, hedge funds, and corporate strategy teams. Visit us at http://www.hdinresearch.com.
2026 AI Transparency Footer:
This intelligence report was authored by HDIN Research analysts following an audit of official corporate filings. AI was utilized for large-scale data synthesis and structural drafting, ensuring 100% inclusion of reported data points. All strategic insights, financial modeling, and final verdicts were verified by our editorial board to ensure professional accuracy and compliance with 2026 Google Search E-E-A-T standards.
1. Jubilant Ingrevia Limited [NSE: JUBLINGREA / BSE: 543271] reported FY2026 consolidated total revenue of $503.52 million (₹4,388 Crore), up 5% YoY, with EBITDA expanding 9% YoY to $69.65 million (₹607 Crore) and operating margin improving 51 basis points to 14%.
2. A structural shift elevated Specialty Chemicals to 75% of total corporate EBITDA, anchored by double-digit volume expansion in Vitamin B3 and continuous flow commercialization at the Bharuch hub, offsetting a 4% EBITDA margin compression in Chemical Intermediates.
3. Balance sheet deleveraging compressed Net Debt by 11% YoY to $67.82 million (0.97x EBITDA), providing operational buffer for a >$229.50 million multi-year capital outlay targeting the "Pinnacle 345" vision to triple revenue by FY2029.
Figure Jubilant Ingrevia Limited FY2026 Financial & Operational Master Blueprint
Segmental Realities, Financial Architecture, and Working Capital DiagnosticsJubilant Ingrevia Limited demonstrated volume-driven top-line growth in FY2026, absorbing deflationary chemical pricing shocks across international markets. Note: All figures are converted at 1 USD = 87.1468 INR. Consolidated Total Revenue reached $503.52 million (₹4,388 Crore / ₹43,880.65 million), up 5% YoY. Profitability metrics scaled across all tiers: Consolidated EBITDA stood at $69.65 million (₹607 Crore), reflecting a 9% YoY growth; Consolidated EBIT reached $49.56 million (₹4,319.04 million); Profit After Tax (PAT) expanded 11% YoY to $31.90 million (₹278 Crore / ₹2,778.99 million). The EBITDA margin expanded by 51 bps to 14%, while net margin remained steady at 6%.
Table Segment Analysis
| Operating Segment | FY2026 Revenue (USD / INR) | Consolidated Revenue Share (%) | FY2026 EBITDA (USD / INR) | Segment EBITDA Share (%) | Segment EBITDA Margin (%) | Primary Volume & Operational Drivers |
| Specialty Chemicals | $222.27M (₹1,937 Crore) | 44% | $58.52M (₹510 Crore) | 75% | 26% | Pyridine and Diketene volume growth; CDMO scaling in Agro, Pharma, and Semiconductor chemistries; EBITDA margin >25% for 6 consecutive quarters. |
| Nutrition & Health Solutions | $90.65M (₹790 Crore) | 18% | $11.47M (₹100 Crore) | 15% | 13% | Vitamin B3 (Niacinamide) volumes reached 8-quarter high; Remidex Pharma acquired for $1.86M to enter premix market. |
| Chemical Intermediates | $190.71M (₹1,662 Crore) | 38% | $8.38M (₹73 Crore) | 11% | 4% | Margin contracted from 7% in FY25 due to Paracetamol market weakness; offset by double-digit Ethyl Acetate volume growth and >70% domestic market share in Acetic Anhydride. |
The company's balance sheet maintains low leverage metrics:
* Net Debt compressed 11% YoY from FY2025 to $67.82 million (₹591 Crore).
* Net Debt-to-EBITDA improved to 0.97x (down from 1.18x in FY2025).
* Consolidated Gearing (Net Debt to Equity) contracted to 0.19x (vs. 0.22x in FY2025).
* Debt Service Coverage Ratio (DSCR) stood at 4.39x.
* Operating Cash Flow (OCF) reached $60.16 million (₹5,242.70 million), achieving high conversion from $69.65 million EBITDA.
* Cash CAPEX Outflows totaled $41.34 million (₹3,602.35 million), delivering Free Cash Flow (FCF) of $18.82 million.
* Consolidated ROCE was recorded at 12.36%, ROE at 9.18%, and Net Capital Turnover Ratio at 14.71x (vs. 16.19x in FY2025 due to ongoing asset commissioning).
Operational working capital compressed to 16% of revenue (down from 18% in FY2025), with net working capital cycle reduced to 59 days (working capital cycle at 62 days vs. 66 days in FY2025).
* Inventory Management: Raw material inventory compressed 8.6% to $36.93 million (₹3,218.45 million); finished goods inventory contracted 15.6% to $33.95 million (₹2,958.69 million). Total inventory write-downs were $0.12 million (₹10.29 million) against a total inventory base of $100.97 million (₹8,799.65 million).
* Receivables & Credit Risk: Undisputed trade receivables <6 months stood at $89.72 million (₹7,818.97 million); 6–12 months receivables totaled $0.09 million (₹7.64 million). Expected Credit Loss (ECL) allowance rose slightly to $0.41 million (₹36.06 million vs. $0.39 million in FY2025), with default provisioning scaled from 0.03% (<6 months) to 32.28% (6–12 months) and 98.67% (>1 year).
* Payables & Supplier Finance: Trade payables stood at $107.94 million (₹9,406.47 million), with Accounts Payable days at 97 days. Supplier financing arrangements covered $52.30 million (₹4,557.81 million) of payables across 90-to-120-day terms.
* Tax & Dividends: Against Profit Before Tax of $42.43 million (₹3,697.40 million), tax expense of $10.54 million (₹918.41 million) yielded an effective tax rate of 24.8% (statutory rate: 25.168%). Non-deductible/exempt items reduced tax liabilities by $1.25 million (₹109.29 million), while foreign sub-rates added $1.10 million (₹95.91 million). The Board declared a final dividend of $0.03 (₹2.50) per share, matching the interim dividend for a total FY2026 payout of $0.06 (₹5.00) per share ($9.14 million / ₹796.41 million total cash allocation), representing a 28.66% payout ratio against PAT of $31.89 million (₹2,778.99 million).
Infrastructure Footprint, R&D Pipeline, and M&A Forensic Audit
Jubilant Ingrevia Limited operates 6 manufacturing hubs (Gajraula, Bharuch, Nira, Savli, Ambernath, Bengaluru) housing over 50 interconnected plants, supported by international distribution hubs in the USA, Belgium, Singapore, and China. Total revenue generated outside India reached 44.32% ($223.16 million / ₹19,447.81 million) across 1,600+ customers in 63 countries. Geographic breakdown: India $284.43 million (₹24,787.18 million / 56.5%); Americas & Europe $161.49 million (₹14,073.52 million / 32.1%); China $19.57 million (₹1,705.36 million / 3.9%); Rest of World $38.03 million (₹3,314.59 million / 7.5%).
Capital expenditure over the last 3 years exceeded $229.50 million (₹2,000+ Crore). Key projects include:
* Bharuch Hub: Commissioned a multipurpose Agro CDMO plant within 14 months (commercial dispatches launched March 2026); operationalized a cGMP Niacinamide facility (WHO-GMP, FSSC 22000 v6, USFDA approved); built a 10MW Captive Power Plant with 98TPH boiler; Multi-Purpose Plant (MPP) under construction.
* Greater Noida Hub: Commenced execution on a clean-room Semiconductor R&D lab for sub-parts-per-billion (ppb) purity chemistries (E-Pyridines, E-Choline Hydroxide).
* Gajraula & Nira Hubs: Installed Variable Frequency Drives on boiler fans, optimized incinerator waste heat recovery, implemented heat recovery systems, and introduced new-age catalysts.
R&D expenditure totaled $4.20 million (₹365.82 million / +4.7% YoY), representing 0.83% of total revenue. Expensed R&D reached $3.69 million (₹321.20 million / 87.8%), while capitalized R&D was $0.51 million (₹44.62 million / 12.2%). R&D operations employ 150 scientists (including 30 PhDs) across 35+ chemistry platforms at 3 centers (Greater Noida, Bharuch, Gajraula). The active pipeline features 50+ products, utilizing continuous flow manufacturing for Niacin/Niacinamide, Agentic AI/GenAI retrosynthesis, and pilot plant testing at Gajraula. Patent disclosures were omitted in filings.
On March 30, 2026, Jubilant Ingrevia Limited acquired 100% of Remidex Pharma Private Limited for a total purchase consideration of $1.868 million (₹162.79 million) [$1.283 million upfront cash; $0.585 million deferred liability]. Acquisition costs of $0.091 million (₹7.93 million) were expensed. Purchase Price Allocation: Net identifiable assets acquired were $1.165 million (₹101.53 million), creating $0.703 million (₹61.26 million) in Goodwill. Assets acquired included PPE of $2.555 million (₹222.63 million), Customer Relationship Intangibles of $0.765 million (₹66.63 million), Other Non-Current Assets of $0.046 million (₹3.99 million), and Current Assets of $0.644 million (₹56.09 million; including $0.181 million inventory, $0.402 million receivables, $0.008 million cash). Identifiable liabilities assumed totaled $2.844 million (₹247.81 million; payables $0.572 million, other financial liabilities $1.148 million). Remidex reported full-year standalone losses of $1.294 million (-₹112.81 million) on revenue of $2.532 million (₹220.62 million), carrying negative net assets of negative $1.162 million (-₹101.30 million). Post-acquisition profit contribution consolidated from March 30–31 was $0.005 million (₹0.45 million).
Table Subsidiary Portfolio Analysis
| Subsidiary Entity | Region | Primary Operating Activity | Total Income (USD / INR) | Net Profit / (Loss) After Tax | Net Asset Base |
| Jubilant Infrastructure Ltd. | India | SEZ Utility & Boiler Provider | $25.91M (₹2,257.91M) | $1.952M (₹170.13M) | $31.00M (₹2,701.44M) |
| Jubilant Agro Sciences Ltd. | India | Crop Protection CDMO | $2.321M (₹202.27M) | -$1.313M (-₹114.40M) | $15.53M (₹1,353.49M) |
| Jubilant Life Sciences NV | Belgium | European Sales & Distribution | $54.72M (₹4,768.99M) | $2.322M (₹202.38M) | $11.12M (₹969.29M) |
| Jubilant Ingrevia (USA) Inc. | USA | Americas Sales & Distribution | $34.70M (₹3,024.18M) | $0.411M (₹35.79M) | $4.74M (₹413.31M) |
| Jubilant Life Sciences (Shanghai) Ltd. | China | China Sales & Distribution | $19.53M (₹1,702.27M) | $0.470M (₹40.96M) | $5.69M (₹495.47M) |
| Jubilant Ingrevia International Pte. Ltd. | Singapore | Holding & Corporate Sales | $0.639M (₹55.66M) | $0.577M (₹50.26M) | $12.28M (₹1,070.47M) |
| Remidex Pharma Private Ltd. | India | Human Nutrition Premixes | $2.532M (₹220.62M)* | $0.005M (₹0.45M)** | -$1.162M (-₹101.30M) |
Related Party Transactions (RPT) in FY2026 totaled $82.19 million (₹7,162.72 million) in operating sales and $38.38 million (₹3,344.88 million) in purchases, executed under arm's-length clearance. Sales to JLS NV (Belgium) reached $43.10 million (₹3,755.94 million), making the subsidiary the parent’s single largest customer (9.08% of parent revenue). Sales to JI-USA were $26.78 million; JLS Shanghai $9.38 million; Jubilant Agri & Consumer Products (JACPL) $2.25 million (₹196.19 million). Purchases included $23.81 million (₹2,075.25 million) paid to Jubilant Infrastructure Ltd for SEZ utilities, $7.65 million from JLS Shanghai, $3.90 million from Jubilant Pharmova, $1.59 million from JACPL, and $0.98 million (₹85.40 million) to AMP Energy for solar PPA. Parent intercompany borrowings from JIL stood at $6.83 million (₹595.00 million) at 6.63%–7.07% interest ($3.04 million repaid, $0.639 million interest paid). Parent loans to JASL totaled $4.70 million (₹410.00 million) outstanding ($3.44 million issued in FY2026, generating $0.210 million interest). Cross-charges generated $4.48 million (₹390.21 million), including $1.01 million to Jubilant Biosys and $0.99 million to Jubilant Pharmova. CSR donations to Jubilant Bhartia Foundation totaled $0.728 million standalone ($0.790 million consolidated).
Promoter group shareholding decreased 6.25% in FY2026, from 51.47% to 45.22%. SPB Trustee Co reduced its stake by 2.28% to 18.35%, while Nikita Resources (2.20%) and Jubilant Enpro (1.77%) liquidated their holdings. HSB Trustee Co retained 19.00%. Zero promoter shares are pledged. The 12-member Board includes 6 Independent Directors (50%), featuring 2 women Independent Directors (Sudha Pillai, Ameeta Chatterjee). Executive compensation: Deepak Jain (CEO & MD) received $1.66 million (₹144.58 million / +13.24% YoY / 146.04x median); Hari S. Bhartia (Co-Chairman) received $2.11 million (₹183.78 million / -0.19% YoY / 185.64x median); Vijay Kumar Srivastava (COO) received $0.38 million (₹33.25 million). Average salary increases were 8.80% for non-managerial staff and 8.91% for managerial staff; median salary was $11,360 (₹0.99 million). Key Managerial Personnel turnover was zero, though Ambrish Dixit (President - Specialty Chemicals) resigned effective March 31, 2026. Permanent employee turnover reached 19.6% (female turnover: 25.2%).
ESG Benchmarks: S&P Global CSA score of 74/100 (97th percentile); EcoVadis Silver (92nd percentile); CDP 'B' for Climate and Water. Scope 1 target: -40% by FY2029 (vs. FY2023). Scope 2 emissions fell 24% YoY, reducing net absolute GHG by ~33,944 tCO2e. Renewable power reached 25% (targeting >35% by FY2029 via equity in O2 Renewable Energy XVIII). Specific water consumption dropped 2.8%–3.6%; recycling reached 45%; 3 of 5 plants operate with Zero Liquid Discharge (ZLD). Process safety audit scored in the 83rd percentile. Lost Time Injury Frequency Rate (LTIFR) stood at 0.00x with zero fatalities. Female workforce participation reached 7.2% (targeting 12% by FY2027 under WINGS).
Macro disruptions included Red Sea war risk surcharges of 7%–8%, feedstock shifts via US 45Z ethanol rules, and coal import regulations. USFDA audit of Bharuch site was completed with Zero 483 observations. Net unhedged FX exposure closed at a USD liability of $3.92 million (₹341.63 million) and EUR asset of $0.43 million (₹37.59 million), leaving a 5% USD fluctuation with a $0.14 million (₹12.37 million) impact on PBT, managed via natural hedges.
HDIN Institutional Verdict
Jubilant Ingrevia Limited's FY2026 performance highlights the execution of its portfolio transformation. The Specialty Chemicals vertical now delivers 75% of operating EBITDA, insulating consolidated profitability from commodity pricing cycles. However, three operational vulnerabilities require ongoing evaluation by institutional investors:
1. Sub-Segment Friction: The Chemical Intermediates margin compression to 4% reflects severe Chinese dumping and weakness in the Paracetamol value chain. While backward integration protects volume continuity, asset turnover in base intermediates remains cyclically suppressed.
2. High Subsidiary and Customer Concentration: Crop protection subsidiary Jubilant Agro Sciences Limited (JASL) depends on two global innovators for 86% of its revenue, requiring financial support guarantees from the parent entity despite posting FY2026 net losses of $1.313 million.
3. Integration and Executive Continuity: Managing the integration of Remidex Pharma (acquired with negative net assets of -$1.162 million) alongside the departure of Ambrish Dixit (President - Specialty Chemicals) presents operational integration hurdles as the company executes its $390.15 million peak revenue CDMO pipeline under the "Pinnacle 345" roadmap.
Presentation Download & Video Access:
- Presentation Download: Click the PDF download link under 'Related Topics' to access the full institutional presentation of this report.
- Video Link: Click this link to watch the HDIN analyst briefing on YouTube.
About HDIN Research:
HDIN Research is a global market intelligence and strategic advisory firm specializing in institutional-grade financial analysis, supply chain audits, and macroeconomic forecasting. Our dedicated sector analysts deliver actionable, data-driven insights tailored for private equity, hedge funds, and corporate strategy teams. Visit us at http://www.hdinresearch.com.
2026 AI Transparency Footer:
This intelligence report was authored by HDIN Research analysts following an audit of official corporate filings. AI was utilized for large-scale data synthesis and structural drafting, ensuring 100% inclusion of reported data points. All strategic insights, financial modeling, and final verdicts were verified by our editorial board to ensure professional accuracy and compliance with 2026 Google Search E-E-A-T standards.